All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-02-06T09:13:01.000Z

Transplant conditioning with treosulfan/fludarabine with or without TBI in patients with AML and MDS

Feb 6, 2018
Share:

Bookmark this article

In an article published in Biology of Blood and Marrow Transplantation, H. Joachim Deeg from Fred Hutchinson Cancer Research Center, Seattle, WA, and colleagues discussed results from their prospective randomized phase II study (NCT01894477), which assessed whether the addition of 2 Gy Total Body Irradiation (TBI) to treosulfan/fludarabine can reduce post-transplant relapse incidence and improve Progression-Free Survival (PFS) in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

This phase II study was initially designed for 80 patients. Patients were randomly assigned to receive either treosulfan (14 g/m2/day, Days -6 to -4) and fludarabine (30 mg/m2/day, Days -6 to -2) alone (Non-TBI arm) or with a single dose of 2 Gy TBI (Day 0 [TBI arm]). A planned preliminary analysis of ≥ 20 patients in each arm who were followed for ≥ 6 months, demonstrated that patients in the TBI arm had a significantly superior PFS (P = 0.04) than patients in the non-TBI arm. As a result, enrolment into the Non-TBI arm was terminated. The protocol of the study was amended to enrol more patients and the remaining were enrolled in the TBI arm. 

Thus, a total of 100 patients (median age = 57 years) with AML (n = 49), MDS (n = 49), and chronic myelomonocytic leukemia (n = 2) were enrolled in this study between December 2013 and July 2016. Patients were randomly assigned to the TBI (n = 65) and Non-TBI arm (n = 35).  

Key findings:

1-year Relapse rate in the TBI and Non-TBI arms respectively

  • In all patients: 22% vs 34%, HR = 0.49, P = 0.06
  • In patients with AML: 16% vs 35%; HR = 0.31, P = 0.05
  • In patients with MDS: 27% vs 33%, HR = 0.11, P = 0.49

1-year Overall Survival (OS) in the TBI and Non-TBI arms, respectively

  • In all patients: 80% vs 69%, HR = 0.71, P = 0.34
  • In patients with AML: 84% vs 65%, HR = 0.40, P = 0.09
  • In patients with MDS: 76% vs 72%, HR = 1.28, P = 0.64

1-year PFS in the TBI and Non-TBI arms, respectively

  • In all patients: 68% vs 54%, HR = 0.64, P = 0.15
  • In patients with AML: 75% vs 53%, HR = 0.42, P = 0.06
  • In patients with MDS: 61% vs 56%, HR = 0.94, P = 0.88 

1-year non-relapse mortality (NRM) in all patient was 9% and did not differ between arms.

Overall, 27 patients died in the TBI and Non-TBI arms due to relapse (7 vs 10), GVHD (8 vs 2), organ failure (2 vs 1), and infection (1 vs 0).

The authors concluded by highlighting that their data confirmed the “excellent tolerability of fludarabine/treosulfan conditioning in patients with AML and MDS”. Furthermore, the addition of 2 Gy TBI to treosulfan/fludarabine appeared to benefit outcomes by reducing relapse risk without increasing toxicity or NRM.

Addition of TBI to fludarabine/treosulfan appeared to benefit patients with AML but had no significant effect in patients with MDS, which the authors noted was “consistent with biological and pathophysiological differences between AML and MDS”.

  1. Deeg H.J. et al. Transplant conditioning with Treosulfan/Fludarabine with or without TBI. A randomized phase II trial in patients with MDS and AML. Biology of Blood and Marrow Transplantation. 2017 Dec 20. DOI: 10.1016/j.bbmt.2017.12.785 [Epub ahead of print]

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox